ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.58
-0.50%
US Tech 100
18,390.40
0.40%
S&P 500
5,306.04
0.02%
US Dollar vs CAD
1.36455
0.12%
Bitcoin
68,277.74
-1.61%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. HOOKIPA Pharma Inc (HOOK)

  7. HOOKIPA Pharma Inc (HOOK) News

HOOK

HOOKIPA Pharma (HOOK)

HOOKIPA Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HOOK
DateTimeSourceHeadlineSymbolCompany
05/23/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
05/23/20244:01PMGlobeNewswire Inc.HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual MeetingNASDAQ:HOOKHOOKIPA Pharma Inc
05/09/20246:04AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOOKHOOKIPA Pharma Inc
05/09/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
05/09/20246:01AMGlobeNewswire Inc.HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:HOOKHOOKIPA Pharma Inc
04/25/20246:01AMGlobeNewswire Inc.HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabNASDAQ:HOOKHOOKIPA Pharma Inc
04/24/20246:01AMGlobeNewswire Inc.HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated CancersNASDAQ:HOOKHOOKIPA Pharma Inc
04/16/20243:30PMGlobeNewswire Inc.HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:HOOKHOOKIPA Pharma Inc
04/10/20246:01AMGlobeNewswire Inc.HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to RegistrationNASDAQ:HOOKHOOKIPA Pharma Inc
03/22/20246:01AMGlobeNewswire Inc.HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:HOOKHOOKIPA Pharma Inc
03/06/20246:01AMGlobeNewswire Inc.HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma ConferenceNASDAQ:HOOKHOOKIPA Pharma Inc
01/31/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
01/29/20247:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
01/29/20247:01AMGlobeNewswire Inc.HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership ProgramsNASDAQ:HOOKHOOKIPA Pharma Inc
01/16/20246:01AMGlobeNewswire Inc.HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationNASDAQ:HOOKHOOKIPA Pharma Inc
01/04/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HOOKHOOKIPA Pharma Inc
12/22/20236:33AMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:HOOKHOOKIPA Pharma Inc
12/21/20236:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
12/21/20236:01AMGlobeNewswire Inc.HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesNASDAQ:HOOKHOOKIPA Pharma Inc
12/01/20233:46PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
11/20/20236:01AMGlobeNewswire Inc.HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency VirusNASDAQ:HOOKHOOKIPA Pharma Inc
11/09/20236:10AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOOKHOOKIPA Pharma Inc
11/09/20236:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
11/09/20236:01AMGlobeNewswire Inc.HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:HOOKHOOKIPA Pharma Inc
11/03/202311:01AMGlobeNewswire Inc.HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023NASDAQ:HOOKHOOKIPA Pharma Inc
11/02/20233:01PMGlobeNewswire Inc.HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023NASDAQ:HOOKHOOKIPA Pharma Inc
10/22/20235:01AMGlobeNewswire Inc.HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023NASDAQ:HOOKHOOKIPA Pharma Inc
10/20/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
10/18/20236:01AMGlobeNewswire Inc.HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead SciencesNASDAQ:HOOKHOOKIPA Pharma Inc
09/13/20237:47AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:HOOK

Your Recent History

NASDAQ
MSFT
Microsoft
COIN
PRCEUR
LSE
NEXN
Nexxen
COIN
BNCEUR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved